Obesity as a determinant for response to antihypertensive treatment.
Why the study?
Does metoprolol reduce blood pressure more effectively than isradipine in obese hypertensive patients compared to lean patients?
Population
42 white men with uncomplicated mild to moderate essential hypertension
Comparison
Metoprolol 50-100 mg twice daily for six weeks vs Isradipine 2.5-5.0 mg twice daily for six weeks
Design
RCT, randomised, Double blind
Follow-up
six weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports obesity-stratified antihypertensive selection; extends evidence for phenotype-specific therapy in hypertension.
Structured PICO
Does metoprolol reduce blood pressure more effectively than isradipine in obese hypertensive patients compared to lean patients?
P
Population
42 white men with uncomplicated mild to moderate essential hypertension (World Health Organisation stage I or II)
I
Intervention
Metoprolol 50-100 mg twice daily for six weeks
C
Comparator
Isradipine 2.5-5.0 mg twice daily for six weeks
O
Outcome
Blood pressure after six weeks of treatmentsurrogate
Obesity status may determine the optimal choice of antihypertensive therapy, with beta blockers being more effective in obese patients and calcium channel blockers in lean patients.
Cite This Study
Schmieder et al. (1993) studied this question.